Pd59-10 Treatment Outcomes in Parkinson’s Disease-Related Overactive Bladder: Sacral Neuromodulation vs. Onabotulinuma Toxin Injections

You have accessJournal of UrologyUrodynamics/Lower Urinary Tract Dysfunction/Female Pelvic Medicine: Neuromodulation (PD59)1 May 2024PD59-10 TREATMENT OUTCOMES IN PARKINSON'S DISEASE-RELATED OVERACTIVE BLADDER: SACRAL NEUROMODULATION VS. ONABOTULINUMA TOXIN INJECTIONS Eiftu Haile, Po-Ming Chow, and Howard Goldman Eiftu HaileEiftu Haile , Po-Ming ChowPo-Ming Chow , and Howard GoldmanHoward Goldman View All Author Informationhttps://doi.org/10.1097/01.JU.0001009544.34256.8a.10AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Parkinson's Disease (PD) is the second-most common degenerative neurologic disease worldwide. Up to 85% of these patients suffer from bothersome lower urinary tract symptoms (LUTS), including overactive bladder (OAB). Sacral Neuromodulation (SNM) and intradetrusor onabotulinumA toxin (BoNTA) injections are two prevalent third-line interventions, yet their comparative efficacy in PD patients remains under-explored. METHODS: A retrospective review of PD patients who failed or did not tolerate medical management and underwent SNM or BoNTA from 2000-2022 was performed. Patient demographics, baseline LUTS, and adverse events were recorded. Primary outcomes included percentage improvement in LUTS and adverse events. RESULTS: 100 patients were included in the final cohort, 45 of whom underwent SNM and 55 who received BoNTA injections. Baseline demographics were comparable between the two groups, with no significant differences in age, sex, Charlson Comorbidity Index (CCI), and various clinical symptoms, including baseline LUTS (OAB, urge/stress/mixed urinary incontinence, acute urinary retention). 82.2% of the SNM group experienced a greater than 50% improvement in symptoms compared to 63.6% in the BoNTA group (p=0.0462). While the BoNTA group had a higher incidence of post-procedural urinary retention (12.73% vs. 0%, p=0.0155), 6 of these 7 patients had pre-existing urinary retention. No significant differences were observed in urinary tract infections between the groups (2.22% vs. 7.27%, p=0.3751). CONCLUSIONS: Both SNM and BoNTA injections provide significant relief for LUTS in PD patients; however, SNM may yield a higher percentage of symptom improvement when compared to BoNTA injections. Both third-line options were well tolerated within this cohort with no differences in adverse events. Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e1225 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Eiftu Haile More articles by this author Po-Ming Chow More articles by this author Howard Goldman More articles by this author Expand All Advertisement PDF downloadLoading ...